Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.

Frontiers in immunology - 1 Jan 2021

Rossi Matteo, Carboni Susanna, Di Berardino-Besson Wilma, Riva Erika, Santiago-Raber Marie-Laure, Belnoue Elodie, Derouazi Madiha

Abstract excerpt

Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response resulting in anti-tumoral efficacy in various mouse models. Intra-tumoral administration of stimulator of interferon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma, Experimental

Share to Th1 Cells

Share to Tumor Burden

Share to Vaccines, Subunit

Source

Open in PubMed Open full text

Identifiers

PMID: 34276686
DOI: 10.3389/fimmu.2021.695056
PMCID: PMC8283310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.PMID 34276686Read ↗

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapySemantic proximity Read ↗

Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effectSemantic proximity Read ↗

Engineering the Immune Adaptor Protein STING as a BiologicSemantic proximity Read ↗

STING pathway agonism as a cancer therapeuticSemantic proximity Read ↗

Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer ImmunotherapySemantic proximity Read ↗

T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapySemantic proximity Read ↗

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of CancerSemantic proximity Read ↗

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate CancerSemantic proximity Read ↗

Strategies for developing and optimizing cancer vaccinesSemantic proximity Read ↗

STING Licensing of Type I Dendritic Cells Potentiates Antitumor ImmunitySemantic proximity Read ↗

Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathwaySemantic proximity Read ↗

Conventional DNA-Damaging Cancer Therapies and Emerging cGAS-STING Activation: A Review and Perspectives Regarding Immunotherapeutic PotentialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.